| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | ADVANCED SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Original Article |
BACKGROUND: There are two distinct DNA topoisomerase II (topo II) isoforms, designated topo IIalpha and topo IIbeta, in mammalian cells. The function of topo IIalpha in the development of mammalian cells has not been elucidated because of a lack of topo IIalpha mutants. RESULTS: We generated mice with a targeted disruption of the topo IIalpha gene. The development of topo IIalpha-/- embryos was terminated at the 4- or 8-cell stage. When wild-type embryos at the 2- or 4-cell stage were treated with ICRF-193, a catalytic inhibitor of topo II, nuclear division occurred followed by cytokinesis to form 4 or 8 cells, respectively, then development was terminated. Microscope analysis of 4,6-diamidino-2-phenylindole (DAPI)-stained nuclei of both topo IIalpha-/- and ICFR-193-treated embryonic cells revealed a droplet-like structure connecting the terminals of two adjacent nuclei forming a bridge-like structure. Phosphorylated histone H3, a marker for the M phases, disappeared from the nuclei of the topo IIalpha-depleted embryonic cells. Laser scanning cytometry of the topo IIalpha-depleted cells revealed the presence of 2N DNA cells. CONCLUSIONS: Our results indicate that topo IIalpha has an essential role in the early stages of mouse development and that depletion of topo IIalpha from the embryonic cells causes incomplete nuclear division followed by enforced cytokinesis.
This article has been cited by other articles:
|
|
 |
|
  S.-W. Park, A. M. Parrott, D. T. Fritz, Y. Park, M. B. Mathews, and C.-G. Lee Regulation of the catalytic function of topoisomerase II alpha through association with RNA Nucleic Acids Res., November 1, 2008; 36(19): 6080 - 6090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Toyoda, S. Kagaya, I. G. Cowell, A. Kurosawa, K. Kamoshita, K. Nishikawa, S. Iiizumi, H. Koyama, C. A. Austin, and N. Adachi NK314, a Topoisomerase II Inhibitor That Specifically Targets the {alpha} Isoform J. Biol. Chem., August 29, 2008; 283(35): 23711 - 23720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Burgess, J. Doles, L. Zender, W. Xue, B. Ma, W. R. McCombie, G. J. Hannon, S. W. Lowe, and M. T. Hemann Topoisomerase levels determine chemotherapy response in vitro and in vivo PNAS, July 1, 2008; 105(26): 9053 - 9058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Liang, X. Wu, J. C. Yalowich, and B. B. Hasinoff A Three-Dimensional Quantitative Structure-Activity Analysis of a New Class of Bisphenol Topoisomerase II{alpha} Inhibitors Mol. Pharmacol., March 1, 2008; 73(3): 686 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Spence, H. H. Phua, W. Mills, A. J. Carpenter, A. C. G. Porter, and C. J. Farr Depletion of topoisomerase II{alpha} leads to shortening of the metaphase interkinetochore distance and abnormal persistence of PICH-coated anaphase threads J. Cell Sci., November 15, 2007; 120(22): 3952 - 3964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Grauslund, A. V. Thougaard, A. Fuchtbauer, K. F. Hofland, P. H. Hjorth, P. B. Jensen, M. Sehested, E.-M. Fuchtbauer, and L. H. Jensen A Mouse Model for Studying the Interaction of Bisdioxopiperazines with Topoisomerase II{alpha} in Vivo Mol. Pharmacol., October 1, 2007; 72(4): 1003 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Linka, A. C.G. Porter, A. Volkov, C. Mielke, F. Boege, and M. O. Christensen C-Terminal regions of topoisomerase II{alpha} and II{beta} determine isoform-specific functioning of the enzymes in vivo Nucleic Acids Res., June 28, 2007; 35(11): 3810 - 3822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Wyles, Z. Wu, S. E.L. Mirski, and S. P.C. Cole Nuclear interactions of topoisomerase II {alpha} and {beta} with phospholipid scramblase 1 Nucleic Acids Res., June 12, 2007; (2007) gkm434v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Creighton-Gutteridge, J. H. Cardellina II, A. G. Stephen, A. Rapisarda, B. Uranchimeg, K. Hite, W. A. Denny, R. H. Shoemaker, and G. Melillo Cell Type-Specific, Topoisomerase II-Dependent Inhibition of Hypoxia-Inducible Factor-1{alpha} Protein Accumulation by NSC 644221 Clin. Cancer Res., February 1, 2007; 13(3): 1010 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Jensen, H. Liang, R. Shoemaker, M. Grauslund, M. Sehested, and B. B. Hasinoff A Three-Dimensional Quantitative Structure-Activity Relationship Study of the Inhibition of the ATPase Activity and the Strand Passing Catalytic Activity of Topoisomerase II{alpha} by Substituted Purine Analogs Mol. Pharmacol., November 1, 2006; 70(5): 1503 - 1513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Carpenter and A. C.G. Porter Construction, Characterization, and Complementation of a Conditional-Lethal DNA Topoisomerase II{alpha} Mutant Human Cell Line Mol. Biol. Cell, December 1, 2004; 15(12): 5700 - 5711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S Hossain, K. Kurokawa, N. Akimitsu, and K. Sekimizu DNA topoisomerase II is required for the G0-to-S phase transition in Drosophila Schneider cells, but not in yeast Genes Cells, October 1, 2004; 9(10): 905 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sakaguchi and A. Kikuchi Functional compatibility between isoform {alpha} and {beta} of type II DNA topoisomerase J. Cell Sci., March 1, 2004; 117(7): 1047 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Adachi, H. Suzuki, S. Iiizumi, and H. Koyama Hypersensitivity of Nonhomologous DNA End-joining Mutants to VP-16 and ICRF-193: IMPLICATIONS FOR THE REPAIR OF TOPOISOMERASE II-MEDIATED DNA DAMAGE J. Biol. Chem., September 19, 2003; 278(38): 35897 - 35902. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | ADVANCED SEARCH | TABLE OF CONTENTS |
